Skip to main content

Table 2 Comparison of treatment effect toward global assessment of improvement and other outcome measures

From: A pilot randomized placebo-controlled study on modified MaZiRenWan: a formulated Chinese medicine to relieve constipation for palliative cancer patients

Variable MZRW group
(n = 27)
Placebo group
(n = 28)
Between-Group Difference
(95% CI)
P value
Primary Outcome
 Global assessment of improvementa, n (%) 16 (59.26%) 8 (28.57%) NA .022
Secondary Outcomes (Changes from baseline)
 Stool frequency, mean (SD) 2.46 (4.59) 0.45 (1.71) 2.02 (0.10 to 3.93) .040
 Bristol stool type, mean (SD) 0.89 (1.37) 0.71 (1.61) 0.17 (− 0.63 to 0.98) .667
 Severity of constipation, mean (SD) − 1.94 (2.22) − 0.82 (1.67) − 1.12 (− 2.19 to -0.05) .040
 Sensation of straining, mean (SD) − 1.09 (1.81) − 0.02 (1.03) − 1.07 (− 1.88 to -0.27) .010
 Incomplete evacuation, mean (SD) − 1.41 (2.28) − 0.46 (2.04) − 0.94 (− 2.11 to 0.23) .112
 Bloating, mean (SD) − 0.80 (1.97) − 0.54 (1.91) − 0.26 (− 1.31 to 0.79) .621
 Abdominal pain/cramping, mean (SD) − 0.26 (1.68) 0.04 (1.43) − 0.29 (− 1.14 to 0.55) .485
 Nauseab, mean (SD) − 0.15 (1.34) 0.07 (1.76) − 0.22 (− 1.07 to 0.63) .606
 Passing of gas, mean (SD) − 0.33 (1.83) − 0.43 (1.70) 0.10 (− 0.86 to 1.05) .843
  1. aP value based on Pearson chi−square test method
  2. bThe difference in baseline has no significant effect on nausea after treatment according to covariance analysis